Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay
Purpose Studies have documented potential drug–drug interactions (pDDIs) occurring in cancer patients mainly with solid malignancies, either in the ambulatory or hospital settings. While hematopoietic stem cell transplant (HSCT) patients during their bone marrow transplantation unit (BMTU) stay have...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2019-05, Vol.83 (5), p.827-835 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 835 |
|---|---|
| container_issue | 5 |
| container_start_page | 827 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 83 |
| creator | Sanchez, Lydia Bacle, Astrid Lamy, Thierry Le Corre, Pascal |
| description | Purpose
Studies have documented potential drug–drug interactions (pDDIs) occurring in cancer patients mainly with solid malignancies, either in the ambulatory or hospital settings. While hematopoietic stem cell transplant (HSCT) patients during their bone marrow transplantation unit (BMTU) stay have rather complex medical regimens combining chemotherapy, anti-infectious agents, immunosuppressive agents, and supportive-care drugs, studies on potential DDIs are lacking. Our objective was to evaluate the prevalence and the density of pharmacokinetic and pharmacodynamic potential DDIs, and the evolution of the renal function in hematopoietic stem cell transplant (HSCT) adult recipients during their BMTU stay.
Methods
Retrospective study in 31 adult patients consecutively admitted to the BMTU.
Results
Prevalence of pharmacokinetic interactions was ten times lower than the pharmacodynamic interactions. The contraindications were rare, and only of pharmacokinetic origin. The main drugs involved in pharmacokinetic DDIs were ciclosporine, methotrexate, esomeprazole, tramadol, and vincristine. The median number of potential nephrotoxicity-related DDIs per patient was 7 and the median number of days during which nephrotoxicity-related DDIs potentially occurred was 77 days per patient. The decrease in glomerular filtration rate (GFR) throughout the BMTU stay (mean decrease of 13 ml/min) was correlated with the number of days of potential nephrotoxic drug interactions.
Conclusions
Potential DDIs in HCST patients in BMTU were quite common. The DDIs from pharmacokinetic origin were less frequent, but of higher grade, than those of pharmacodynamic origin. The decrease in GFR suggests that the density of potential nephrotoxic drug interactions may be an issue to be considered in these patients. |
| doi_str_mv | 10.1007/s00280-019-03791-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02061952v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2179175188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-60ee43db3b5a1af22edb6cc0f3871492866c70f799e9b016d5b09dfb5ed314543</originalsourceid><addsrcrecordid>eNp9kb9uFDEQhy0EIkfgBSiQJaoUC-O194_LKAKCdBIUUFteezbnaM9ebC_hOt4hFa_Hk-DlQqCiGsn-5jej-Qh5zuAVA-heJ4C6hwqYrIB3klXyAdkwwesKesEfkg1wIaqmA3FCnqR0DQCCcf6YnHDomr4VckN-fAwZfXZ6ojYuVz-_366FOp8xapNd8Ilqb6nHeRdDDt-ccflQ_ukO9zqHOTjMztCUcU8NThPNUfs0T9pnqu0yZRrRuNmVIYnaJTp_RYfgke51jOHmH1yv0-jiXS5p-vCUPBr1lPDZXT0ln9---XRxWW0_vHt_cb6tjOhkrlpAFNwOfGg002Ndox1aY2DkfceErPu2NR2MnZQoB2CtbQaQdhwatJyJRvBTcnbM3elJzdGVvQ4qaKcuz7dqfYMaWiab-isr7MsjO8fwZcGU1XVYoi_rqZoVA13D-r5Q9ZEyMaQUcbyPZaBWc-poThVz6rc5JUvTi7voZdijvW_5o6oA_AikeT0ixr-z_xP7Cyp9qOw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179175188</pqid></control><display><type>article</type><title>Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Sanchez, Lydia ; Bacle, Astrid ; Lamy, Thierry ; Le Corre, Pascal</creator><creatorcontrib>Sanchez, Lydia ; Bacle, Astrid ; Lamy, Thierry ; Le Corre, Pascal</creatorcontrib><description>Purpose
Studies have documented potential drug–drug interactions (pDDIs) occurring in cancer patients mainly with solid malignancies, either in the ambulatory or hospital settings. While hematopoietic stem cell transplant (HSCT) patients during their bone marrow transplantation unit (BMTU) stay have rather complex medical regimens combining chemotherapy, anti-infectious agents, immunosuppressive agents, and supportive-care drugs, studies on potential DDIs are lacking. Our objective was to evaluate the prevalence and the density of pharmacokinetic and pharmacodynamic potential DDIs, and the evolution of the renal function in hematopoietic stem cell transplant (HSCT) adult recipients during their BMTU stay.
Methods
Retrospective study in 31 adult patients consecutively admitted to the BMTU.
Results
Prevalence of pharmacokinetic interactions was ten times lower than the pharmacodynamic interactions. The contraindications were rare, and only of pharmacokinetic origin. The main drugs involved in pharmacokinetic DDIs were ciclosporine, methotrexate, esomeprazole, tramadol, and vincristine. The median number of potential nephrotoxicity-related DDIs per patient was 7 and the median number of days during which nephrotoxicity-related DDIs potentially occurred was 77 days per patient. The decrease in glomerular filtration rate (GFR) throughout the BMTU stay (mean decrease of 13 ml/min) was correlated with the number of days of potential nephrotoxic drug interactions.
Conclusions
Potential DDIs in HCST patients in BMTU were quite common. The DDIs from pharmacokinetic origin were less frequent, but of higher grade, than those of pharmacodynamic origin. The decrease in GFR suggests that the density of potential nephrotoxic drug interactions may be an issue to be considered in these patients.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-019-03791-9</identifier><identifier>PMID: 30758649</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Bone marrow ; Bone marrow transplantation ; Cancer ; Cancer Research ; Chemotherapy ; Density ; Drug Interactions ; Drug-Related Side Effects and Adverse Reactions - epidemiology ; Drug-Related Side Effects and Adverse Reactions - etiology ; Drugs ; Glomerular filtration rate ; Glomerular Filtration Rate - drug effects ; Hematologic Neoplasms - therapy ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Humans ; Immunosuppressive agents ; Intensive Care Units - statistics & numerical data ; Kidney - drug effects ; Length of Stay ; Life Sciences ; Medicine ; Medicine & Public Health ; Methotrexate ; Middle Aged ; Omeprazole ; Oncology ; Original Article ; Patients ; Pharmaceutical Preparations - administration & dosage ; Pharmaceutical Preparations - metabolism ; Pharmaceutical sciences ; Pharmacodynamics ; Pharmacology ; Pharmacology/Toxicology ; Renal function ; Retrospective Studies ; Stem cell transplantation ; Stem cells ; Tramadol ; Transplantation ; Transplants & implants ; Vincristine</subject><ispartof>Cancer chemotherapy and pharmacology, 2019-05, Vol.83 (5), p.827-835</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-60ee43db3b5a1af22edb6cc0f3871492866c70f799e9b016d5b09dfb5ed314543</citedby><cites>FETCH-LOGICAL-c479t-60ee43db3b5a1af22edb6cc0f3871492866c70f799e9b016d5b09dfb5ed314543</cites><orcidid>0000-0003-4483-0957</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-019-03791-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-019-03791-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30758649$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-rennes.hal.science/hal-02061952$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanchez, Lydia</creatorcontrib><creatorcontrib>Bacle, Astrid</creatorcontrib><creatorcontrib>Lamy, Thierry</creatorcontrib><creatorcontrib>Le Corre, Pascal</creatorcontrib><title>Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose
Studies have documented potential drug–drug interactions (pDDIs) occurring in cancer patients mainly with solid malignancies, either in the ambulatory or hospital settings. While hematopoietic stem cell transplant (HSCT) patients during their bone marrow transplantation unit (BMTU) stay have rather complex medical regimens combining chemotherapy, anti-infectious agents, immunosuppressive agents, and supportive-care drugs, studies on potential DDIs are lacking. Our objective was to evaluate the prevalence and the density of pharmacokinetic and pharmacodynamic potential DDIs, and the evolution of the renal function in hematopoietic stem cell transplant (HSCT) adult recipients during their BMTU stay.
Methods
Retrospective study in 31 adult patients consecutively admitted to the BMTU.
Results
Prevalence of pharmacokinetic interactions was ten times lower than the pharmacodynamic interactions. The contraindications were rare, and only of pharmacokinetic origin. The main drugs involved in pharmacokinetic DDIs were ciclosporine, methotrexate, esomeprazole, tramadol, and vincristine. The median number of potential nephrotoxicity-related DDIs per patient was 7 and the median number of days during which nephrotoxicity-related DDIs potentially occurred was 77 days per patient. The decrease in glomerular filtration rate (GFR) throughout the BMTU stay (mean decrease of 13 ml/min) was correlated with the number of days of potential nephrotoxic drug interactions.
Conclusions
Potential DDIs in HCST patients in BMTU were quite common. The DDIs from pharmacokinetic origin were less frequent, but of higher grade, than those of pharmacodynamic origin. The decrease in GFR suggests that the density of potential nephrotoxic drug interactions may be an issue to be considered in these patients.</description><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Density</subject><subject>Drug Interactions</subject><subject>Drug-Related Side Effects and Adverse Reactions - epidemiology</subject><subject>Drug-Related Side Effects and Adverse Reactions - etiology</subject><subject>Drugs</subject><subject>Glomerular filtration rate</subject><subject>Glomerular Filtration Rate - drug effects</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Intensive Care Units - statistics & numerical data</subject><subject>Kidney - drug effects</subject><subject>Length of Stay</subject><subject>Life Sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methotrexate</subject><subject>Middle Aged</subject><subject>Omeprazole</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Pharmaceutical Preparations - administration & dosage</subject><subject>Pharmaceutical Preparations - metabolism</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacodynamics</subject><subject>Pharmacology</subject><subject>Pharmacology/Toxicology</subject><subject>Renal function</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Tramadol</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><subject>Vincristine</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kb9uFDEQhy0EIkfgBSiQJaoUC-O194_LKAKCdBIUUFteezbnaM9ebC_hOt4hFa_Hk-DlQqCiGsn-5jej-Qh5zuAVA-heJ4C6hwqYrIB3klXyAdkwwesKesEfkg1wIaqmA3FCnqR0DQCCcf6YnHDomr4VckN-fAwZfXZ6ojYuVz-_366FOp8xapNd8Ilqb6nHeRdDDt-ccflQ_ukO9zqHOTjMztCUcU8NThPNUfs0T9pnqu0yZRrRuNmVIYnaJTp_RYfgke51jOHmH1yv0-jiXS5p-vCUPBr1lPDZXT0ln9---XRxWW0_vHt_cb6tjOhkrlpAFNwOfGg002Ndox1aY2DkfceErPu2NR2MnZQoB2CtbQaQdhwatJyJRvBTcnbM3elJzdGVvQ4qaKcuz7dqfYMaWiab-isr7MsjO8fwZcGU1XVYoi_rqZoVA13D-r5Q9ZEyMaQUcbyPZaBWc-poThVz6rc5JUvTi7voZdijvW_5o6oA_AikeT0ixr-z_xP7Cyp9qOw</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Sanchez, Lydia</creator><creator>Bacle, Astrid</creator><creator>Lamy, Thierry</creator><creator>Le Corre, Pascal</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0003-4483-0957</orcidid></search><sort><creationdate>20190501</creationdate><title>Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay</title><author>Sanchez, Lydia ; Bacle, Astrid ; Lamy, Thierry ; Le Corre, Pascal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-60ee43db3b5a1af22edb6cc0f3871492866c70f799e9b016d5b09dfb5ed314543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Density</topic><topic>Drug Interactions</topic><topic>Drug-Related Side Effects and Adverse Reactions - epidemiology</topic><topic>Drug-Related Side Effects and Adverse Reactions - etiology</topic><topic>Drugs</topic><topic>Glomerular filtration rate</topic><topic>Glomerular Filtration Rate - drug effects</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Intensive Care Units - statistics & numerical data</topic><topic>Kidney - drug effects</topic><topic>Length of Stay</topic><topic>Life Sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methotrexate</topic><topic>Middle Aged</topic><topic>Omeprazole</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Pharmaceutical Preparations - administration & dosage</topic><topic>Pharmaceutical Preparations - metabolism</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacodynamics</topic><topic>Pharmacology</topic><topic>Pharmacology/Toxicology</topic><topic>Renal function</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Tramadol</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanchez, Lydia</creatorcontrib><creatorcontrib>Bacle, Astrid</creatorcontrib><creatorcontrib>Lamy, Thierry</creatorcontrib><creatorcontrib>Le Corre, Pascal</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanchez, Lydia</au><au>Bacle, Astrid</au><au>Lamy, Thierry</au><au>Le Corre, Pascal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>83</volume><issue>5</issue><spage>827</spage><epage>835</epage><pages>827-835</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Purpose
Studies have documented potential drug–drug interactions (pDDIs) occurring in cancer patients mainly with solid malignancies, either in the ambulatory or hospital settings. While hematopoietic stem cell transplant (HSCT) patients during their bone marrow transplantation unit (BMTU) stay have rather complex medical regimens combining chemotherapy, anti-infectious agents, immunosuppressive agents, and supportive-care drugs, studies on potential DDIs are lacking. Our objective was to evaluate the prevalence and the density of pharmacokinetic and pharmacodynamic potential DDIs, and the evolution of the renal function in hematopoietic stem cell transplant (HSCT) adult recipients during their BMTU stay.
Methods
Retrospective study in 31 adult patients consecutively admitted to the BMTU.
Results
Prevalence of pharmacokinetic interactions was ten times lower than the pharmacodynamic interactions. The contraindications were rare, and only of pharmacokinetic origin. The main drugs involved in pharmacokinetic DDIs were ciclosporine, methotrexate, esomeprazole, tramadol, and vincristine. The median number of potential nephrotoxicity-related DDIs per patient was 7 and the median number of days during which nephrotoxicity-related DDIs potentially occurred was 77 days per patient. The decrease in glomerular filtration rate (GFR) throughout the BMTU stay (mean decrease of 13 ml/min) was correlated with the number of days of potential nephrotoxic drug interactions.
Conclusions
Potential DDIs in HCST patients in BMTU were quite common. The DDIs from pharmacokinetic origin were less frequent, but of higher grade, than those of pharmacodynamic origin. The decrease in GFR suggests that the density of potential nephrotoxic drug interactions may be an issue to be considered in these patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30758649</pmid><doi>10.1007/s00280-019-03791-9</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4483-0957</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2019-05, Vol.83 (5), p.827-835 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02061952v1 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Bone marrow Bone marrow transplantation Cancer Cancer Research Chemotherapy Density Drug Interactions Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - etiology Drugs Glomerular filtration rate Glomerular Filtration Rate - drug effects Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Immunosuppressive agents Intensive Care Units - statistics & numerical data Kidney - drug effects Length of Stay Life Sciences Medicine Medicine & Public Health Methotrexate Middle Aged Omeprazole Oncology Original Article Patients Pharmaceutical Preparations - administration & dosage Pharmaceutical Preparations - metabolism Pharmaceutical sciences Pharmacodynamics Pharmacology Pharmacology/Toxicology Renal function Retrospective Studies Stem cell transplantation Stem cells Tramadol Transplantation Transplants & implants Vincristine |
| title | Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A40%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20drug%E2%80%93drug%20interactions%20and%20nephrotoxicity%20in%20hematopoietic%20stem%20cell%20transplant%20adult%20recipients%20during%20bone%20marrow%20transplantation%20unit%20stay&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Sanchez,%20Lydia&rft.date=2019-05-01&rft.volume=83&rft.issue=5&rft.spage=827&rft.epage=835&rft.pages=827-835&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-019-03791-9&rft_dat=%3Cproquest_hal_p%3E2179175188%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2179175188&rft_id=info:pmid/30758649&rfr_iscdi=true |